350 Épisodes

  1. 346: Zealand's obesity strategy and Immunovant's curious development plan

    Publié: 20/03/2025

  2. 345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies

    Publié: 13/03/2025

  3. 344: Trump's FDA commissioner nominee takes the hot seat

    Publié: 06/03/2025

  4. 343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs

    Publié: 27/02/2025

  5. 342: FDA cuts, zombie biotechs, and too much weight loss?

    Publié: 20/02/2025

  6. 341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers

    Publié: 13/02/2025

  7. 340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

    Publié: 06/02/2025

  8. 339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

    Publié: 30/01/2025

  9. 338: Chinese biotechs, a WHO departure, and post-JPM thoughts

    Publié: 23/01/2025

  10. 337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

    Publié: 15/01/2025

  11. 336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

    Publié: 09/01/2025

  12. 335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

    Publié: 19/12/2024

  13. 334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

    Publié: 12/12/2024

  14. 333: An H5N1 bird flu update and talent scarcity in the radiopharma field

    Publié: 05/12/2024

  15. 332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

    Publié: 21/11/2024

  16. 331: AbbVie’s stumble, Amgen’s tumble and more election fallout

    Publié: 14/11/2024

  17. 330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

    Publié: 07/11/2024

  18. 329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

    Publié: 31/10/2024

  19. 328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

    Publié: 24/10/2024

  20. 327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

    Publié: 17/10/2024

1 / 18

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Visit the podcast's native language site